NCT06897813

A Phase I Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-910 in Healthy Participants

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 68 (estimated)
• Sponsor: Zhejiang Wenda Pharma Technology LTD. · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a phase I, randomised, double-blind, placebo-controlled, 3-part study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of WD-910 in in Healthy Participants Detailed

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	WD-910 tablet	Administered P.O.
DRUG	WD-910 Tablets Placebo	Administered P.O.

Timeline

• Start date: 2025-06-30
• Primary completion: 2025-10-31
• Completion: 2025-12-31
• First posted: 2025-03-27
• Last updated: 2025-04-02

Locations

1 site across 1 country: Australia